Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 26, Issue , 2015, Pages v69-v77

  Parker, C ^a   Gillessen, S ^b   Heidenreich, A ^c   Horwich, A ^d  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; CABAZITAXEL; CORTICOSTEROID; DOCETAXEL; ENZALUTAMIDE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM; RADIUM 223; SIPULEUCEL T; TECHNETIUM; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALOPECIA; ANDROGEN DEPRIVATION THERAPY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER SCREENING; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; EARLY DIAGNOSIS; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FOLLOW UP; HEART DISEASE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOKALEMIA; MALE; METASTASIS; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL EDEMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; THROMBOCYTOPENIA; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS;

HUMANS; MALE; NEOPLASM STAGING; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84941276341     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv222     Document Type: Article

References (48)

1. Schröder FH, Hugosson J, Roobol MJ et al. Screening and prostate cancer mortality: results of the European Randomised Study of screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384: 2027-2035.
2. Andriole GL, Crawford ED, Grubb RL, 3rd et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104: 125-132.
3. Lilja H, Cronin AM, Dahlin A et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011; 117: 1210-1219.
4. Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-534.
5. Sonn GA, Chang E, Natarajan S et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol 2014; 65: 809-815.
6. Epstein JI, Allsbrook WC, Jr, Amin MB et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-1242.
7. D'Amico AV, Whittington R, Malkovicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
8. Edge SB, Byrd DR, Compton CC (eds). AJCC Cancer Staging Handbook, 7th edition. New York, NY: Springer 2010.
9. Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update. Eur Urol 2014; 65: 124-137.
10. Suardi N, Capitanio U, Chun FK et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 2008; 113: 2068-2072.
11. Bill-Axelson A, Holmberg L, Garmo H et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014; 370: 932-942.
12. Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-213.
13. Steineck G, Helgesen F, Adolfsson J et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790-796.
14. Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301-308.
15. Warde P, Mason M, Ding K et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378: 2104-2111.
16. Denham JW, Steigler A, Lamb DS et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised controlled trial. Lancet Oncol 2011; 12: 451-459.
17. Roach M, III, Bae K, Speight J et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. JCO 2008; 26: 585-591.
18. Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972-3978.
19. Bolla M, de Reijke TM, Van Tienhoven G et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-2527.
20. Bolla M, van Poppel H, Tombal B et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018-2027.
21. Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial. J Urol 2009; 181: 956-962.
22. Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-2930.
23. Trock BJ, Han M, Freedland SJ et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-2769.
24. Moul JW, Wu H, Sun L et al. Early versus delayed hormonal therapy for prostate antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 1141-1147.
25. Crook JM, O'Callaghan CJ, Duncan G et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012; 367: 895-903.
26. Hussain M, Tangen CM, Higano CS et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients ( pts): results of S9346 (INT-0162), an international phase III trial. N Engl J Med 2013; 368: 1314-1325.
27. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491-1498.
28. Sweeney C, Chen Y-H, Carducci M et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. J Clin Oncol (ASCO Meeting Abstracts) 2014; 32 (18 suppl): LBA2.
29. Gravis G, Fizazi K, Joly F et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 149-158.
30. James ND, Sydes MR, Mason MD et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 2015; 33 (suppl; abstract 5001)
31. Galvao DA, Taaffe DR, Spry N et al. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010; 28: 340-347.
32. Venkitaraman R, Lorente D, Murthy V et al. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol 2015; 67: 673-679.
33. Ryan CJ, Smith MR, Fizazi K et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castrationresistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152-160.
34. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-433.
35. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
36. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223.
37. Tannock IF, de Witt R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
38. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
39. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
40. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
41. Chow E, Harris K, Fan G et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007; 25: 1423-1436.
42. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.
43. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
44. Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 2003; 23: 2028-2037.
45. Beltran H, Tagawa ST, Park K et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012; 30: e386-e389.
46. Doneux A, Parker CC, Norman A et al. The utility of digital rectal examination after radical radiotherapy for prostate cancer. Clin Oncol (R Coll Radiol) 2005; 17: 172-173.
47. Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol 2007; 8: 1007-1017.
48. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.